NASDAQ:ANTX Anthem Q3 2026 Earnings Results & Report $4.27 +0.27 (+6.77%) As of 03:11 PM Eastern This is a fair market value price provided by Massive. Learn more. Anthem reported Q3 2026 earnings on November 9, 2026. The company reported EPS of -$0.17. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 9, 2026TimeBefore Market OpensConference Call7:00 AM ET Anthem EPS ResultsActual EPS-$0.17Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersAnthem Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Anthem Q3 2026 Earnings FAQ Did Anthem beat earnings estimates for Q3 2026? Anthem (NASDAQ:ANTX) reported earnings of -$0.17 per share for Q3 2026. The report was announced on Monday, November 9, 2026. Anthem Earnings HeadlinesAN2 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business and Scientific HighlightsNovember 9 at 8:00 AM | businesswire.comAN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4)October 23, 2026 | businesswire.comExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December. The agenda at the upcoming G20 Summit in Miami has shifted, and new research points to a major monetary announcement from President Trump. A new documentary breaks down what this shift could mean for savings, investments, and the assets tied to it.November 10 at 1:00 AM | Porter & Company (Ad)SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of AN2 Therapeutics, Inc. (NASDAQ: ANTX)October 12, 2026 | prnewswire.comAN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSKSeptember 28, 2026 | businesswire.comAN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)September 16, 2026 | businesswire.comSee More Anthem Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Anthem? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Anthem and other key companies, straight to your email. Email Address About AnthemAn2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company that traded on the Nasdaq under the symbol ANTX. The company focused on developing novel treatments for serious infectious diseases, with its lead candidate, epetraborole, designed as an oral therapy for pulmonary disease caused by nontuberculous mycobacteria (NTM). Epetraborole was evaluated in clinical studies involving patients with refractory Mycobacterium avium complex pulmonary disease, a difficult-to-treat infection that primarily affects the lungs. An2 Therapeutics received regulatory designations intended to support development of the therapy, including Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration. The company was founded in 2017 and was headquartered in Menlo Park, California. Eric Easom served as co-founder, president and chief executive officer. An2 Therapeutics announced that it was discontinuing development of epetraborole after results from its EBO-301 study did not support continued development. The company name provided does not match the Nasdaq symbol ANTX, which has been associated with An2 Therapeutics.View Anthem ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles DraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?Wall Street May Be Making a Big Mistake With monday.com StockCloudflare's 20% Sell-Off May Have Created an Opening for InvestorsMarketBeat Week in Review – 11/2 - 11/6 Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
